April 25, 2022
The PMPRB has responded to the statement made April 14, 2022, by the Federal Minister
of Health, Minister Duclos regarding the Coming-into-Force of the Regulations Amending
the Patented Medicines Regulations.
March 28, 2022
On March 24, 2022, the Supreme Court of Canada dismissed the application by the Attorney General of Canada in its appeal to the Federal Court Decision in the SOLIRIS case.
February 25, 2022
The Quebec Court of Appeal has confirmed that is it unconstitutional for the PMPRB to compel companies to provide information from 3rd party agreements.
December 24, 2021
On December 23, 2021, the Minister of Health, Jean-Yves Duclos announced a delay in the coming-into-force of the Regulations Amending the Patented Medicines Regulations by six months.
December 20, 2021
On December 17, 2021, the PMPRB posted an update that read, “The Board has decided not to proceed with the changes that were proposed in the July 15, 2021 Notice and Comment.
August 5, 2021
Read about the two major announcements have been made in the last couple of weeks pertaining to the PMPRB.
July 28, 2021
CADTH has announced the establishment of a Special Advisory Panel to design a potential pan-Canadian formulary.
June 28, 2021
The PMPRB has updated their website to state the coming-into-force of the amended Patented Medicines Regulations has been further delayed until January 1, 2022.
May 28, 2021
Twitter was abuzz with a letter from Christopher MacLeod, Canadian Cystic Fibrosis Treatment Society to the President of the Treasury Board, House of Commons & the Auditor General Canada with a request to investigate PMPRB for “targeting & de-legitimizing the Patient Voice”.
May 19, 2021
Quebec will be moving to a biosimilars only program by April 12, 2022.